[Response evaluation--pathway for accurate indications development].
Only patients, which respond to neoadjuvant therapy and in which a subsequent complete resection (R0) is possible, demonstrate a significant survival advantage compared to non-responders. Therefore, a sensitive response evaluation is of high clinical interest. Response evaluation by endoscopy, biopsy, endoluminal ultrasound or by CT scan showed unfavourable and overall nor reliable results. In recent studies, a accurate response prediction employing 18FDG-PET seems to be possible. Following neoadjuvant chemoradiation of esophageal cancer, a sensitive differentiation between responders and non-responders was possible in a retrospective study. In the beginning are investigations, to differentiate already after two weeks of therapy between both groups of patients.
Sendler
A
A
Chirurgische Klinik und Poliklinik, Technische Universität München, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 München.
D003131:Combined Modality Therapy; D019091:Critical Pathways; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005069:Evaluation Studies as Topic; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010043:Outcome and Process Assessment, Health Care; D015996:Survival Rate